|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | G01N 33/50 | |
| G01N 33/564 |
| (11) | Patento numeris | 2425250 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10716450.1 |
| Europos patento paraiškos padavimo data | 2010-04-27 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-03-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-02-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/032572 |
| Data | 2010-04-27 |
| (87) | Numeris | WO 2010/126890 |
| Data | 2010-11-04 |
| (30) | Numeris | Data | Šalis |
| 173138 P | 2009-04-27 | US |
| (72) |
SHERIDAN III, James Peter, US
|
| (73) |
AbbVie Biotherapeutics Inc.,
1500 Seaport Boulevard, Redwood City, CA 94063,
US
|
| (54) | METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS |
| METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS |